1999

Vanderkwaak TJ, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh VN, Barnes MN , Siegal GP, Alvarez RD , Curiel DT: An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gyn Oncol 74:227-234, 1999.

Partridge EE, Barnes MN : Epithelial ovarian cancer: Prevention, diagnosis, and treatment. CA Cancer J Clin 49:297-316, 1999.

2000

Alvarez RD , Barnes MN , Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT: A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody (sFv) encoding adenovirus (AD21): A phase I trial. Clin Cancer Res 6:3081-3087, 2000.

Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT: Adenoviral-mediated suicide gene therapy for ovarian cancer. Molec Therapy 2:524-530, 2000.

Arafat WO, Gomez-Navarro J, Xiang J, Barnes MN , Mahasreshti P, Alvarez RD , Siegal GP, Badib AO, Buchsbaum DJ, Curiel DT, Stackhouse MA: An adenovirus encoding proapoptotic bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Mol Ther 1:545-554, 2000.

Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN , Alvarez RD , Curiel DT: Selectivity of TAG-72 targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 6:4323-4333, 2000.

Rodriguez-Buford C, Barnes M, Oellschlager R, Myers R, Partridge E, Grizzle W Growth inhibition of ovarian cancer cells by non-steroidal anti-inflammatory agents (NSAIDS): In vitro evaluation as potential chemopreventive agents. American Association of Cancer Research (AACR). New Orleans , LA 2000.

Rodriguez-Buford C, Barnes M, Oellschlager R, Myers R, Partridge E, Grizzle W. Growth inhibition of ovarian cancer cells by non-steroidal anti-inflammatory agents (NSAIDS): In vitro evaluation as potential chemopreventive agents. 8 th SPORE Investigators Workshop. Chantilly , VA 2000.

2001

Rodriguez-Burford C, Barnes MN , Berry W, Partridge EE, Grizzle WE: Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gyn Oncology, 81(3):373-79, 2001.

Straughn JM Jr, Richter HE, Conner MG, Meleth S, Barnes MN: Predictors of outcome in small cell carcinoma of the cervix, a case series. Gyn Onc 83:216-220, 2001.

Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker S, Wang MH, Mahasreshi PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Siegal GP, Alvarez RD, Curiel DT: Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 7:2496-2504, 2001.

Rodriguez-Burford C, Chhieng D, Stockard C, Barnes M, Alvarez R, Partridge H, Weiss H, Grizzle W: Association between p53 and erbB-2 in primary and matched metastatic lesions in ovarian carcinoma. American Association of Cancer Research. New Orleans , LA 2001.

Burford C, Barnes M, Berry W, Partridge E, Grizzle W. Gallus domesticus. A potential model of spontaneous ovarian carcinogenesis for the preclinical evaluation of cancer chemoprevention. Society of Gynecologic Oncologist. Nashville TN 2001.

Burford C, Barnes M, Talley L, Partridge E, Grizzle W. A selective COX-2 inhibitor demonstrates inhibition of ovarian tumor cell growth. 9 th SPORE Investigators Workshop, Washington DC , 2001.

2002

Burford C, Barnes M, Oelschlager D, Myers R, Talley L, Partridge E, Grizzle W: Effects of non-steroidal anti-inflammatory agents (NSAIDS) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8:202-209, 2002.

Barnes MN , Berry WD, Straughn JM, Kirby TO, Leath CA , Huh WK, Grizzle WE, Partridge EE: A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol 87:57-63, 2002.

Barnes MN , Grizzle WE, Grubbs CJ, Partridge EE: Paradigms for primary prevention of ovarian carcinoma. Ca: A Cancer Journal for Clinicians 52:216-225, 2002.

Barnes M, Grizzle W, Grubbs C, Partridge E: Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 52:216-225, 2002.

Barnes M, Berry W, Straughn J, Kirby T, Leath C, Huh W, Grizzle W, Partridge E: A controlled trial of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. American Society of Clinical Oncology. Orlando FL 2002.

Chhieng D, Burford C, Stockard C, Barnes M, Sviglin H, Talley L, Alvarez R, Partridge E, Grizzle W: Expression of therapeutic targets in primary and matched metastatic lesions of ovarian carcinoma. 10 th SPORE Investigators Workshop, Wash DC 2002.

Barnes M, Berry W, Straughn J, Kirby T, Leath C, Huh W, Grizzle W, Partridge E: A controlled trial of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. 10 th SPORE Investigators Workshop, Wash DC 2002.

Barnes M, Powell B, Partridge L, Foaud M, Partridge E: Clinical trials in the screening and prevention of ovarian cancer in high risk women. Morehouse School of Medicine, Tuskegee University , Univ of Alabama at Birmingham Partnership, Summer Institute 2002. Tuskegee AL , 2002.

2003

Barnes M, Berry W, Burford C, Partridge E, Grizzle W: A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. NICHD/WRHR Scholars Research Symposium. Bethesda MD 2003.

Barnes M, Chheing D, Miller E, Grizzle W, Jones L, Partridge E: A controlled clinical trial of celecoxib as a chemopreventive agent in women at elevated risk of ovarian carcinoma: Evaluation of enrollment into a pilot study. 11 th SPORE Investigators Workshop. Baltimore MD 2003.

Miller E, Suarez-Cuervo C, Singh R, Reyes V, Barnes M, Grizzle W: Effects of celebrex in ovarian carcinoma cell lines. 11 th SPORE Investigators Workshop. Baltimore MD 2003.

Barnes M, Chheing D, Miller E, Grizzle W, Jones L, Kilgore, L. Partridge E: Evaluation of the molecular effects of a COX-2 inhibitor on ovarian epithelium in women at elevated risk for ovarian cancer. Report of progress in a controlled clinical trial. Challenging cancer disparities: Genetics, bioethics and Community Relationships. Summer Institute. Morehouse School of Medicine , Atlanta GA 2003.

2004

Barnes M, Chheing D, Riaz V, Dreher M, Grizzle W, Jones L, Partridge E: A controlled clinical trial of celecoxib as a chemopreventive agent in women at elevated risk of ovarian cancer. Society of Gynecologic Oncology, San Diego CA 2004.

Skates S, Horick N, Finkelstein D, Lu K ( ROCA study Group): Prospective multi-center high risk ovarian cancer screening trial: preliminary results from the first 2,000 women. Society of Gynecologic Oncology, San Diego CA 2004.

Barnes M, Chheing D, Jones J, Riaz V, Dreher M, Grizzle W, Jones L, Talley L, Partridge E. A controlled clinical trial of celecoxib as a chemopreventive agent for ovarian cancer: A feasibility study in women at elevated risk. 12 th SPORE Investigators Workshop. Baltimore MD 2004.